Detailed price information for Annovis Bio Inc (ANVS-N) from The Globe and Mail including charting and trades.
Annovis Bio (ANVS) stock slipped after the company said the FDA accepted its updated protocol for a Phase 3 trial for its ...
Annovis Bio (ANVS) announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain ...
MALVERN, Pa – Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company with a market capitalization of $66 million, announced today that it has obtained a U.S. patent for its drug ...
Annovis Bio (ANVS) announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap. This newly issued patent is based ...
Annovis Bio, Inc. MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative ...
MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for ...
Annovis Bio (NYSE:ANVS) announced Tuesday that the U.S. Food and Drug Administration (FDA) accepted an updated protocol for a pivotal Phase 3 trial for its Alzheimer's candidate, buntanetap.
Annovis Bio has a 1 year low of $4.21 and a 1 year high of $20.00. Annovis Bio ( NYSE:ANVS – Get Free Report ) last released its quarterly earnings results on Friday, November 8th.
In recent trading, Annovis Bio Inc (ANVS) stock price has shown some volatility, fluctuating -0.59% over the last five trades and -13.2 ...
MALVERN, Pa – Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company with a market capitalization of $66 million, announced today that it has obtained a U.S. patent for its drug ...